Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6003
Source ID: NCT00141232
Associated Drug: Atorvastatin And Omega-3 Fatty Acids
Title: Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Acronym: AFORRD
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes, Type 2
Interventions: DRUG: Atorvastatin and Omega-3 fatty acids
Outcome Measures: Primary: Prim objective (16 wks) for atorvastatin: Proportion of pats. who achieve measured|LDL levels <2.6 mmol/L (<100 mg/dl) Prim object (16 wks) for Omega-3 fatty acid:|Prop of pats. who achieve measured triglycerides <1.5 mmol/L (<200 mg/dl) | Secondary: Prop of pats who achieve LDL levels <2.6 mmol/L (<100 mg/dl) at 52 weeks, taking into account whether the patient received additional atorvastatin therapy or placebo at week 16.|Prop of pats who achieve triglycerides <1.5 mmol/L (<200 mg/dl) at 52 weeks.
Sponsor/Collaborators: Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Collaborators: Churchill Hospital
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 810
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE|Primary Purpose: TREATMENT
Start Date: 2004-11
Completion Date: 2006-07
Results First Posted:
Last Update Posted: 2021-02-18
Locations: Pfizer Investigational Site, Irvine, Ayrshire, KA12 OAY, United Kingdom|Pfizer Investigational Site, Farnworth, Bolton, BL4 9AH, United Kingdom|Pfizer Investigational Site, Thornhill, Cardiff, CF14 9BB, United Kingdom|Pfizer Investigational Site, Fowey, Cornwall, PL23 1DT, United Kingdom|Pfizer Investigational Site, Launceston, Cornwall, PL15 9HH, United Kingdom|Pfizer Investigational Site, Penzance, Cornwall, TR18 4JH, United Kingdom|Pfizer Investigational Site, Penzance, Cornwall, TR19 7HX, United Kingdom|Pfizer Investigational Site, Saltash, Cornwall, PL12 6DL, United Kingdom|Pfizer Investigational Site, St Austell, Cornwall, PL26 7RL, United Kingdom|Pfizer Investigational Site, Darlington, County Durham, DL16 6QA, United Kingdom|Pfizer Investigational Site, Newton Aycliffe, County Durham, DL5 5NH, United Kingdom|Pfizer Investigational Site, Three Bridges, Crawley, RH10 1LL, United Kingdom|Pfizer Investigational Site, Plymouth, Devon, PL5 3JB, United Kingdom|Pfizer Investigational Site, Plymouth, Devon, PL6 7TH, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, East Sussex, TN39 4SP, United Kingdom|Pfizer Investigational Site, Bexhill-On-Sea, East Sussex, TN40 2SD, United Kingdom|Pfizer Investigational Site, Bath, England, BA2 4JT, United Kingdom|Pfizer Investigational Site, Dronfield, Sheffield, England, S18 1RU, United Kingdom|Pfizer Investigational Site, Surrey, England, CR7 7JN, United Kingdom|Pfizer Investigational Site, Halstead, Essex, CO9 1EX, United Kingdom|Pfizer Investigational Site, Stonehouse, Gloucestershire, GL10 2NG, United Kingdom|Pfizer Investigational Site, Southampton, Hampshire, SO31 7DQ, United Kingdom|Pfizer Investigational Site, Hildenborough, Kent, TN11 9HL, United Kingdom|Pfizer Investigational Site, Thorneton-Clevely, Lancashire, FY5 3LF, United Kingdom|Pfizer Investigational Site, Balham, London, SW12 8EU, United Kingdom|Pfizer Investigational Site, Fulham, London, SW6 2HQ, United Kingdom|Pfizer Investigational Site, Tooting, London, SW17 9SJ, United Kingdom|Pfizer Investigational Site, Hayes, Middlesex, UB4 0SF, United Kingdom|Pfizer Investigational Site, Wellingborough, Northamptonshire, NN8 4RW, United Kingdom|Pfizer Investigational Site, Cookstown, Northern Ireland, BT80 8BN, United Kingdom|Pfizer Investigational Site, Frome, Somerset, BA11 1EZ, United Kingdom|Pfizer Investigational Site, Fetcham, Surrey, KT22 9LE, United Kingdom|Pfizer Investigational Site, Woking, Surrey, United Kingdom|Pfizer Investigational Site, Crawley, West Sussex, RH10 7DX, United Kingdom|Pfizer Investigational Site, Leeds, West Yorkshire, LS12 1JE, United Kingdom|Pfizer Investigational Site, Bradford-on-Avon, Wiltshire, BA1 5DQ, United Kingdom|Pfizer Investigational Site, Melksham, Wiltshire, SN12 6UN, United Kingdom|Pfizer Investigational Site, Swindon, Wiltshire, SN25 4YZ, United Kingdom|Pfizer Investigational Site, Trowbridge, Wiltshire, BA14 7EG, United Kingdom|Pfizer Investigational Site, Warminster, Wiltshire, BA12 9AA, United Kingdom|Pfizer Investigational Site, Sheffield, Yorkshire, S7 2DW, United Kingdom|Pfizer Investigational Site, Bath, BA2 1NH, United Kingdom|Pfizer Investigational Site, Bath, BA2 3HT, United Kingdom|Pfizer Investigational Site, Belfast, BT4 1NT, United Kingdom|Pfizer Investigational Site, Birmingham, B37 7TR, United Kingdom|Pfizer Investigational Site, Bucks, HP22 5LB, United Kingdom|Pfizer Investigational Site, Chesterfield, S40 4TF, United Kingdom|Pfizer Investigational Site, Chippenham, Wiltshire, SN15 2SB, United Kingdom|Pfizer Investigational Site, Cornwall, TR18 2RE, United Kingdom|Pfizer Investigational Site, County Antrim, Northern Ireland, BT41 3AE, United Kingdom|Pfizer Investigational Site, Darlington, DL3 6HZ, United Kingdom|Pfizer Investigational Site, Dundee, DD2 5NH, United Kingdom|Pfizer Investigational Site, Dundee, DD4 6QY, United Kingdom|Pfizer Investigational Site, East Sussex, TN40 3RJ, United Kingdom|Pfizer Investigational Site, Isle Of Wight, PO32 6RR, United Kingdom|Pfizer Investigational Site, Isle Of Wight, PO33 2PT, United Kingdom|Pfizer Investigational Site, London, N19 5EW, United Kingdom|Pfizer Investigational Site, London, SW19 6DA, United Kingdom|Pfizer Investigational Site, Westbury, BA13 3JD, United Kingdom
URL: https://clinicaltrials.gov/show/NCT00141232

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D320 Atorvastatin small molecule DB01076 Details